182 related articles for article (PubMed ID: 21380539)
1. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
[TBL] [Abstract][Full Text] [Related]
2. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
[TBL] [Abstract][Full Text] [Related]
3. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
4. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
5. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
6. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
[TBL] [Abstract][Full Text] [Related]
8. Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Clayton LM; Devile M; Punte T; de Haan GJ; Sander JW; Acheson JF; Sisodiya SM
Ophthalmology; 2012 Oct; 119(10):2152-60. PubMed ID: 22853973
[TBL] [Abstract][Full Text] [Related]
9. Examining visual field defects in the paediatric population exposed to vigabatrin.
Spencer EL; Harding GF
Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
[TBL] [Abstract][Full Text] [Related]
10. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Riise P; Fledelius HC; Rogvi-Hansen Bà
Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
[TBL] [Abstract][Full Text] [Related]
11. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Frisén L
Acta Ophthalmol Scand; 2004 Feb; 82(1):54-8. PubMed ID: 14738486
[TBL] [Abstract][Full Text] [Related]
12. Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
Conway ML; Hosking SL; Zhu H; Cubbidge RP
BMC Ophthalmol; 2014 Dec; 14():166. PubMed ID: 25539569
[TBL] [Abstract][Full Text] [Related]
13. Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.
Wild JM; Fone DL; Aljarudi S; Lawthom C; Smith PE; Newcombe RG; Lewis GD
CNS Drugs; 2013 Oct; 27(10):841-9. PubMed ID: 23990316
[TBL] [Abstract][Full Text] [Related]
14. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Conway M; Cubbidge RP; Hosking SL
Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
[TBL] [Abstract][Full Text] [Related]
15. Visual field defects in patients taking vigabatrin.
Midelfart A; Midelfart E; Brodtkorb E
Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
[TBL] [Abstract][Full Text] [Related]
16. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
[TBL] [Abstract][Full Text] [Related]
17. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
[TBL] [Abstract][Full Text] [Related]
18. Visual field defects in pediatric patients on vigabatrin monotherapy.
Ascaso FJ; Lopez MJ; Mauri JA; Cristobal JA
Doc Ophthalmol; 2003 Sep; 107(2):127-30. PubMed ID: 14661902
[TBL] [Abstract][Full Text] [Related]
19. Visual field constriction in 91 Finnish children treated with vigabatrin.
Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
[TBL] [Abstract][Full Text] [Related]
20. A controlled study of vigabatrin and visual abnormalities.
Manuchehri K; Goodman S; Siviter L; Nightingale S
Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
